Viking Therapeutics, Inc. $VKTX Position Lessened by Allianz Asset Management GmbH

Allianz Asset Management GmbH trimmed its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 25.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,002 shares of the biotechnology company’s stock after selling 24,361 shares during the period. Allianz Asset Management GmbH owned 0.06% of Viking Therapeutics worth $1,908,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Harbour Investments Inc. lifted its stake in shares of Viking Therapeutics by 2.2% in the 2nd quarter. Harbour Investments Inc. now owns 14,961 shares of the biotechnology company’s stock valued at $396,000 after purchasing an additional 326 shares during the last quarter. RFG Advisory LLC increased its holdings in shares of Viking Therapeutics by 64.0% during the 2nd quarter. RFG Advisory LLC now owns 65,039 shares of the biotechnology company’s stock worth $1,724,000 after purchasing an additional 25,387 shares during the period. CWM LLC increased its holdings in shares of Viking Therapeutics by 79.4% during the 2nd quarter. CWM LLC now owns 6,355 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 2,813 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Viking Therapeutics by 34.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 14,607 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 3,779 shares during the period. Finally, Concurrent Investment Advisors LLC increased its holdings in shares of Viking Therapeutics by 5.4% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 9,590 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 488 shares during the period. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Price Performance

Shares of VKTX opened at $34.42 on Friday. The stock’s 50-day moving average is $28.57 and its two-hundred day moving average is $28.79. The stock has a market cap of $3.87 billion, a PE ratio of -16.24 and a beta of 0.64. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.73.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). During the same period last year, the firm earned ($0.22) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. On average, research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VKTX. Cantor Fitzgerald set a $105.00 target price on shares of Viking Therapeutics in a research report on Thursday. B. Riley upgraded shares of Viking Therapeutics to a “strong-buy” rating in a research report on Thursday. JPMorgan Chase & Co. decreased their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research report on Friday. BTIG Research reaffirmed a “buy” rating and set a $125.00 price objective on shares of Viking Therapeutics in a research note on Monday, September 22nd. Finally, Citigroup upped their price objective on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.62.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.